Effects of Olmesartan Medoxomil, an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus: A Preliminary, Observational, Open-Label Study

By Kawai Toshihide   Takei Izumi   Shimada Akira  

Clinical Drug Investigation, Vol. 31, Iss. 4, 2011-04 ,pp. : 237-245

Adis International

Access to resources Recommend Favorite

Dose-Response Characteristics of Olmesartan Medoxomil and Other Angiotensin Receptor Antagonists

By Smith David H.G.  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 5, 2007-01 ,pp. : 347-356

Adis International

Access to resources Recommend Favorite

The Telmisartan Renoprotective Study from Incipient Nephropathy to Overt Nephropathy – Rationale, Study Design, Treatment Plan and Baseline Characteristics of the Incipient to Overt: Angiotensin II Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) Study

By Makino H   Haneda M   Babazono T   Moriya T   Ito S   Iwamoto Y   Kawamori R   Takeuchi M   Katayama S  

The Journal of International Medical Research, Vol. 33, Iss. 6, 2005-11 ,pp. : 677-686

Field House Publishing

Access to resources Recommend Favorite

Olmesartan Medoxomil

By Warner G.T.   Jarvis B.  

Drugs, Vol. 62, Iss. 9, 2002-01 ,pp. : 1345-1353

Adis International

Access to resources Recommend Favorite

Comparative Cost Effectiveness of Angiotensin II Receptor Blockers in a US Managed Care Setting: Olmesartan Medoxomil Compared with Losartan, Valsartan, and Irbesartan

By Simons W.R.  

PharmacoEconomics, Vol. 21, Iss. 1, 2003-01 ,pp. : 61-74

Adis International

Access to resources Recommend Favorite